EPCAM and prostate carcinoma: Using a prostate cancer, EpCAM+ PC-3 xenograft model, we first confirmed that EpCAM-targeted PLGA particles localized within the tumour 3 h post injection using in vivo fluorescence imaging (Supplementary Fig. 15a).